Zydus Lifesciences falls after US FDA warning to Baddi units

Shares of Zydus Lifesciences experienced a decline in market value. The drop follows a regulatory development involving the company. The company's Baddi-based units have received a warning letter. This letter was issued by the United States Food and Drug Administration. The communication highlights compliance concerns at the manufacturing facilities. Investors reacted negatively to the news of the regulatory action. Business Standard reported on the subsequent impact on stock performance. The company may need to address the FDA's observations to stabilize.